Filtered By:
Specialty: Research
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 130 results found since Jan 2013.

'Enzyme Whisperer' Named a Finalist for First-Ever National Blavatnik Award for Young Scientists - 5/21/14
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
Source: Johns Hopkins Medicine News - May 21, 2014 Category: Research Source Type: news

Safety and efficacy in ablation of premature ventricular contraction: data from the German ablation registry.
CONCLUSION: Based on the data from this registry, ablation of PVCs is a safe and efficient procedure with an excellent outcome and improved symptoms after 12 months. PMID: 27484499 [PubMed - as supplied by publisher]
Source: Clin Med Res - August 1, 2016 Category: Research Authors: Fichtner S, Senges J, Hochadel M, Tilz R, Willems S, Eckardt L, Deneke T, Lewalter T, Dorwarth U, Reithmann C, Brachmann J, Steinbeck G, Kääb S, German Ablation Registry Tags: Clin Res Cardiol Source Type: research

State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
CONCLUSION: This study contributes to the growing literature on secondary prevention add-on therapy, as results from these modeling analyses suggest adding vorapaxar to SC for patients at high atherothrombotic risk can provide long-term health benefits. PMID: 28277861 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - March 10, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Comparison of Effectiveness and Safety of Treatment with Apixaban vs. Other Oral Anticoagulants Among Elderly Nonvalvular Atrial Fibrillation Patients.
CONCLUSIONS: In the real-world setting after controlling for differences in patient characteristics, apixaban is associated with significantly lower risk of S/SE and MB than rivaroxaban and warfarin, and a trend towards better outcomes vs. dabigatran among elderly NVAF patients in the US. PMID: 28535119 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 25, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
CONCLUSIONS: In the real-world setting after controlling for differences in patient characteristics, apixaban is associated with significantly lower risk of S/SE and MB than rivaroxaban and warfarin, and a trend towards better outcomes vs. dabigatran among elderly NVAF patients in the US. PMID: 28849676 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - August 31, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
CONCLUSIONS: In this large practice-based population of AF patients prescribed OACs for primary prevention of stroke and systemic embolization, subsequent risk of VTE was lowest among those prescribed apixaban and dabigatran, while risk was similar with prescriptions for warfarin and rivaroxaban. Among AF patients prescribed OACs, lowering risk of VTE may be an additional benefit of apixaban and dabigatran, beyond the reduced bleeding risk observed in randomized clinical trials. PMID: 30362847 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - October 27, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Contrast-free, echocardiography-guided left atrial appendage occlusion (LAAo): a propensity-matched comparison with conventional LAAo using the AMPLATZER ™ Amulet™ device.
CONCLUSIONS: Echocardiographically guided LAAo without the use of contrast dye appears safe and feasible. This approach appears to be associated with reduced radiation exposure and may represent an alternative to traditional LAAo, especially in patients in whom the avoidance of contrast dye is warranted. PMID: 30536045 [PubMed - as supplied by publisher]
Source: Clin Med Res - December 10, 2018 Category: Research Authors: Sedaghat A, Al-Kassou B, Vij V, Nelles D, Stuhr M, Schueler R, Omran H, Schrickel JW, Hammerstingl C, Nickenig G Tags: Clin Res Cardiol Source Type: research

Real-world-study-comparing-NOACs-in-AF-patients
Independent large real-world study comparing NOACs in AF-patientsA recently published large retrospective comparative study investigated stroke, bleeding and mortality risks in older US Medicare patients treated with commonly marketed oral anticoagulants for non-valvular atrial fibrillation1  Results of the real-world study showed that Pradaxa ® (dabigatran etexilate) was associated with a more favourable benefit-risk profile in comparison to both warfarin and rivaroxaban1Data from an earlier FDA-funded Medicare study published in 2015, which investigated cardiovascular, bleeding and mortality risks among patients treate...
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

Ultrasonography for Detecting Adhesions: Aspirin Continuation for Lung Resection Patients
Conclusion: Preoperative detection of pleural adhesions using ultrasonography was useful in selecting pulmonary resection patients who continued aspirin perioperatively.
Source: In Vivo - April 25, 2019 Category: Research Authors: YASUKAWA, M., TAIJI, R., MARUGAMI, N., KAWAGUCHI, T., KAWAI, N., SAWABATA, N., TOJO, T., TAKAHAMA, J., HAMAZAKI, N., HIRAI, T., TANIGUCHI, S. Tags: Clinical Studies Source Type: research

Early signatures of bleeding and mortality in patients on left ventricular assist device support: novel methods for personalized risk-stratification.
CONCLUSIONS: Early trends in routine bloodwork and platelet function may serve as novel signatures of patients at risk to experience adverse events. PMID: 31055944 [PubMed - as supplied by publisher]
Source: Biomarkers - May 6, 2019 Category: Research Tags: Biomarkers Source Type: research

Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
CONCLUSION: This study demonstrated the value of supplementing longitudinal site-based clinical studies with administrative claims data. Our results suggest that claims data together with network partner electronic health record data constitute an effective vehicle to capture patient outcomes since >30% of patients have non-fatal and fatal events outside of enrolling sites. PMID: 31081367 [PubMed - as supplied by publisher]
Source: Clinical Trials - May 12, 2019 Category: Research Authors: Ma Q, Chung H, Shambhu S, Roe M, Cziraky M, Jones WS, Haynes K Tags: Clin Trials Source Type: research

NOAC-vs-ASA-in-ESUS-trial-results-published-in-NEJM
Trial results of Pradaxa ® vs ASA in ESUS published in NEJMFirst Phase III randomised clinical trial to compare dabigatran etexilate and acetylsalicylic acid (ASA)  No significant difference in recurrent stroke prevention after ESUSDabigatran showed no significant difference in major bleeding
Source: Boehringer Ingelheim Corporate News - May 16, 2019 Category: Research Source Type: news

Pericytes in Hereditary Hemorrhagic Telangiectasia.
Authors: Galaris G, Thalgott JH, Lebrin FPG Abstract Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by multi-systemic vascular dysplasia affecting 1 in 5000 people worldwide. Individuals with HHT suffer from many complications including nose and gastrointestinal bleeding, anemia, iron deficiency, stroke, abscess, and high-output heart failure. Identification of the causative gene mutations and the generation of animal models have revealed that decreased transforming growth factor-β (TGF-β)/bone morphogenetic protein (BMP) signaling and increased vascular endothelial growth factor ...
Source: Advances in Experimental Medicine and Biology - June 1, 2019 Category: Research Tags: Adv Exp Med Biol Source Type: research

Warfarin therapy in Chinese patients with atrial fibrillation treated with percutaneous coronary intervention: a 5-year follow-up retrospective cohort study.
Conclusions: Warfarin reduces the incidence of MACCEs but does not increase bleeding events in Chinese patients with AF who underwent PCI. For patients taking warfarin, recurrent myocardial infarction and a baseline CHA2DS2-VASc score >4 were related to MACCE occurrence. PMID: 31144555 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 1, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Worsening renal function, adverse clinical events, and major determinants for changes of renal function in patients with atrial fibrillation: a Japanese multicenter registry substudy.
Conclusion: Age ≥75 years, body weight ≤50 kg, a history of heart failure, and initially preserved renal function appear to promote renal dysfunction in patients with AF, but a history of AF ablation seems to have a favorable effect. Worsening renal function seems to increase AF patients' risk of adverse clinical events. Renal function can decline quickly; thus, early intervention including AF ablation is warranted. PMID: 31204852 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 18, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research